At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 167 enrolled
Drug / intervention
ETX-018810 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain
In Brief
A Phase 2 clinical trial evaluating ETX-018810 and Placebo for Diabetic Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy. Completed, enrolled 167 participants across 22 sites.
Detailed Summary
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedDec 2020
Primary CompletionFeb 2022
Study CompletionFeb 2022
TodayJul 2026
First PostedDec 30, 2020
Enrollment StartNov 9, 2020
Primary CompletionFeb 9, 2022
Study CompletionFeb 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.5 years ago
Interventions
ETX-018810drug
Study Drug
Placebodrug
Matching Placebo